COMMUNIQUÉS West-GlobeNewswire

BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
28/01/2026
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT regimen continues under [...]
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
28/01/2026
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues [...]
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
28/01/2026
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifilimab has the [...]
OMass Therapeutics Appoints Jonathan Montagu as Chair of the Board of Directors
28/01/2026
OXFORD, United Kingdom, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins [...]
OKYO Pharma Announces Successful Type C Meeting with the FDA
28/01/2026
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage [...]
Newly published research further validates GlucoModicum’s path to high-precision, non-invasive glucose monitor
28/01/2026
The study explains the mechanism behind up to 100× sensitivity amplification in glucose sensors The article was published in Biosensors and Bioelectronics , the leading peer-reviewed journal in the field GlucoModicum [...]
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
28/01/2026
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd (SIX: IDIA) [...]
HepatoBurn Investigated (SAFETY REPORT) Is This Liver Formula Legit? Side Effects, Risks, and Warnings Explained
28/01/2026
Las Vegas, Nevada, Jan. 28, 2026 (GLOBE NEWSWIRE) -- If you are researching HepatoBurn reviews in 2026 , you are not alone. Interest in this supplement has surged quietly, not because of viral ads or influencer hype, [...]
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
28/01/2026
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental [...]
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
28/01/2026
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has [...]
Profound Medical Announces Upcoming Investor Events
27/01/2026
TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
27/01/2026
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were [...]
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
27/01/2026
OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to [...]
Premier Health Reports 2025 Fourth Quarter Results
27/01/2026
MONTRÉAL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its Audited Annual Consolidated Financial [...]
The Association of American Physicians and Surgeons (AAPS) Supports ACIP Vaccine Panel Chairman, Kirk Milhoan, M.D.
27/01/2026
TUCSON, Ariz., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to a January 23 New York Times article strongly criticizing pediatric cardiologist Kirk Milhoan, M.D., appointed by HHS Secretary Robert F. Kennedy, Jr., to [...]
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
27/01/2026
Proposed $1.0 million Convertible Debenture and concurrent $500,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets Execution [...]
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
27/01/2026
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
27/01/2026
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on [...]
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
27/01/2026
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday [...]

Pages